We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

9468:TSEKadokawa Corporation Analysis

Data as of 2026-06-19 - not real-time

¥3,278.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Kadokawa’s share price sits well above its DCF-derived fair value, indicating a pronounced overvaluation. The trailing P/E of several hundred times far exceeds the industry average, while the forward P/E remains high despite a projected earnings surge. Revenue is growing at a double‑digit pace and the forward EPS outlook suggests a sharp earnings acceleration. However, operating margins are still negative and free cash flow is in the red, raising concerns about cash generation. The dividend payout ratio is well above 300%, which is unsustainable given the current cash flow profile.
Technical indicators show a neutral market stance, with the MACD turning mildly bullish and the RSI hovering around the midpoint. Volume has been rising, but the price remains trapped between a solid support level near 3,050 and resistance around 3,450. Volatility is elevated at over 35% and the beta is low, suggesting price swings are driven more by company‑specific factors than market moves. Sector exposure to publishing and digital media carries medium risk, while regulatory and geographic risks are relatively low. Overall, the stock appears overvalued with limited upside, making a defensive stance prudent. For investors seeking short‑term exposure, a hold is advisable pending clearer earnings momentum. Longer horizons are better served by a cautious sell recommendation until valuation aligns with fundamentals.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • neutral technical momentum
  • pronounced overvaluation
  • increasing volume but limited upside

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • expected earnings acceleration
  • still stretched valuation
  • cash flow constraints

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • significant overvaluation vs DCF
  • weak cash generation and high debt
  • low ROE limiting returns

Key Metrics & Analysis

Financial Health

Revenue Growth12.00%
Profit Margin0.45%
P/E Ratio376.8
ROE1.47%
ROA0.83%
Debt/Equity3.95
P/B Ratio1.9
Op. Cash Flow¥3.4B
Free Cash Flow¥-11175374848
Industry P/E16.7

Technical Analysis

TrendNeutral
RSI49.3
Support¥3,054.00
Resistance¥3,453.00
MA 20¥3,252.80
MA 50¥3,400.26
MA 200¥3,324.26
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46

Valuation

Fair Value¥1,077.65
Target Price¥3,194.29
Upside/Downside-2.55%
GradeOvervalued
TypeBlend
Dividend Yield1.93%

Risk Assessment

Beta0.25
Volatility35.23%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.